SCHEMBL342111

SCHEMBL342111

CCCCN(CC(C)(C)C=O)C(C)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.41
CA1 P00915 3/20 0.41
CA9 Q16790 3/20 0.41
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP3 P08254 1/20 0.39
MMP8 P22894 1/20 0.39
LMNA P02545 1/20 0.35
ALDH1A1 P00352 1/20 0.33
ALDH2 P05091 1/20 0.33
CA2 P00918 1/20 0.32
ZDHHC20 Q5W0Z9 1/20 0.31
ZDHHC2 Q9UIJ5 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL343034 0.78 CA2 (0.38) CA1LMNAALDH1A1CA2
SCHEMBL497913 0.76 CA12 (0.58) CA12CA1CA9MMP1MMP2
SCHEMBL15426402 0.76 CA12 (0.45) CA12CA1CA9MMP1MMP2
SCHEMBL343340 0.75 CA12 (0.34) CA12CA1CA9
SCHEMBL541168 0.74 CA12 (0.38) CA12CA1CA9LMNAALDH1A1
Hydrochloric Acid SCHEMBL3023639 0.74 CA12 (0.56) CA12CA1CA9MMP1MMP2
SCHEMBL2562443 0.73 GGPS1 (0.33)
SCHEMBL13055373 0.72 CA12 (0.54) CA12CA1CA9MMP1MMP2
SCHEMBL498627 0.72 CA12 (0.54) CA12CA1CA9MMP1MMP2
SCHEMBL2421822 0.72 MEN1 (0.31) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP claimed
CN-103261145-B There is the amine of secondary aliphatic amino group SIKA TECHNOLOGY AG (CH) 2016-04-13 CN claimed
US-9290603-B2 Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-03-22 US claimed
EP-2651875-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-09-12 US claimed
CN-103261145-A Amines having secondary aliphatic amino groups SIKA TECHNOLOGY AG 2013-08-21 CN claimed
WO-2012080264-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465842-A1 Amines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
US-8157950-B2 Aldimine and composition containing aldimine SIKA TECHNOLOGY AG (CH) 2012-04-17 US claimed
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2011-10-20 US claimed
EP-2194082-B1 Aldimine and composition comprising aldimine SIKA TECHNOLOGY AG (CH) 2011-09-07 EP claimed
WO-2010063741-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2010-06-10 WO claimed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP claimed
EP-2651875-B1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-30 EP disclosed
EP-2414418-B1 COMPOSITION CURABLE IN TWO STAGES COMPRISING A SURFACE DEACTIVATED POLYISOCYANATE SIKA TECH AG (CH) 2017-08-09 EP disclosed
CN-103261145-B There is the amine of secondary aliphatic amino group SIKA TECHNOLOGY AG (CH) 2016-04-13 CN disclosed
EP-2236535-A1 Humidity curing polyurethane composition being accelerated by influence of heat Sika Technology AG (CH) 2010-10-06 EP disclosed
EP-2236533-A1 Heat curing or heat activatable composition comprising a surface deactivated polyisocyanate Sika Technology AG (CH) 2010-10-06 EP disclosed
WO-2010063741-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE SIKA TECHNOLOGY AG (CH) 2010-06-10 WO disclosed
EP-2194082-A1 Aldimine and composition comprising aldimine Sika Technology AG (CH) 2010-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237681-A1 AMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS AAAS, PNMT, PARG CA12 3833/4885CA1 3359/4885CA9 3839/4885
US-20110253309-A1 ALDIMINE AND COMPOSITION CONTAINING ALDIMINE ALDH7A1, ALDH3A1, ADH5 CA12 1993/4885CA1 1903/4885CA9 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.